Live
- BJP MP candidate Bharat Prasad visited the student who tried to commit suicide
- PM’s popularity in the fast lane: Autos with 'Har Dil Mein Modi' slogan spotted across Delhi
- Delhi-based political parties are like East India Company: Sukhbir Badal
- Golf: Diksha moves into Top-20 at South African Women’s Open
- KCR lashes out against BJP and Congress for destroying Telangana
- Dairy Science students visited the Milk cooling plant
- Moody feels Pant ahead in keepers’ race for T20 WC squad; Srikkanth picks Rahul over Samson as reserve keeper
- Thanking voters for extending 'unparalleled support' to NDA, PM Modi says second phase 'too good'
- Natural Relief for Menstrual Cramps: Beetroot Juice Recipe
- Asha Worker died in a road accident
Biovet to invest Rs 200 crores for facility expansion
Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Hyderabad: Biovet Private Limited, an animal vaccine maker, announced that it would invest Rs 200 crore as part of its expansion plans to meet the growing market demand for the vaccine which tackles Foot & Mouth Disease (FMD) and Brucellosis in animals.
Biovet informed that it commenced the work towards expanding the FMD vaccine manufacturing facility in Malur, Karnataka.
Krishna Ella, Founder, Biovet, said: "Expansion of our FMD vaccine facilities to deliver 200 million doses is an important step to increase our contribution to meet the shortage of this vaccine in the country."
The company based in Bengaluru will construct a new Brucella Vaccine Production facility at the Malur site to produce 100 million doses.
The vaccine maker said that according to estimates, India's FMD control programme requires 1,000 million doses every year, whereas the current production capacity manufactured in the country is only around 500 million doses.
There is an unmet need for 500 million doses, and Biovet aims to fulfil this gap.
